Glargine U300

DRUG3 trials

Sponsors

Emory University, University of Split, School of Medicine, Medanta, The Medicity, India

Conditions

Diabetes Mellitus, Type 2Type 2 Diabetes

Phase 4

Glargine U300 Hospital Trial

CompletedNCT03013985

Emory UniversityType 2 Diabetes

Start: 2017-05-17End: 2019-03-22Updated: 2020-05-07

Insulin Glargine U300 vs Insulin Degludec U100 in Impact on the Glycaemic and Cardiovascular Factors

CompletedNCT04692415

University of Split, School of MedicineDiabetes Mellitus, Type 2

Start: 2018-12-15End: 2019-06-27Updated: 2020-12-31

Unknown Phase

Degludec Glargine U300 Hospital Study

CompletedNCT05036876

Medanta, The Medicity, IndiaType 2 Diabetes

Start: 2021-10-10End: 2022-03-01Updated: 2024-12-09

Related Papers

Comparison of the Impact of Insulin Degludec U100 and Insulin Glargine U300 on Glycemic Variability and Oxidative Stress in Insulin-Naive Patients With Type 2 Diabetes Mellitus: Pilot Study for a Randomized Trial

JMIR Formative Research2022-07-081 citations

The differences between insulin glargine U300 and insulin degludec U100 in impact on the glycaemic variability, arterial stiffness and the lipid profiles in insulin naïve patients suffering from type two diabetes mellitus - outcomes from cross-over open-label randomized trial.

2021-04-291 citations